sorafenib has been researched along with Familial Nonmedullary Thyroid Cancer in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (68.18) | 24.3611 |
| 2020's | 7 (31.82) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HJ; Chang, HS; Fang, S; Kim, M; Kim, SY; Kim, Y; Park, KC; Yun, HJ | 1 |
| Caterino, M; Ciardiello, F; Facchini, S; Fasano, M; Lo Giudice, G; Pirozzi, M; Rauso, R; Sica, A; Varriale, E; Zotta, A | 1 |
| Choi, KH; Kim, CW; Kim, SM; Kim, SY; Lee, JH; Lim, JH; Pan, CH; Park, K; Park, KC; Weicker, R; Yun, HJ | 1 |
| Chen, Y; Hao, J; Hu, L; Li, H; Lin, Q; Xie, W; Yun, X; Zeng, Y | 1 |
| Chang, HJ; Chang, HS; Kim, Y; Lee, SY; Park, KC; Yun, HJ | 1 |
| Akhanlı, P; Bayır, Ö; Çakal, E; Düğer, H; Kertmen, H; Kızılgül, M; Korkmaz, MH; Saylam, G; Sencar, ME; Uçan, B; Yazılıtaş, D; Yılmazer, D | 1 |
| Choi, KH; Kim, CW; Kim, SM; Kim, Y; Lee, JH; Park, KC; Weicker, R; Yun, HJ | 1 |
| Chayahara, N; Goto, H; Hirokawa, M; Imamura, Y; Ito, Y; Kasahara, T; Kiyota, N; Minami, H; Miya, A; Miyauchi, A; Mukohara, T; Nagatani, Y; Nibu, KI; Otsuki, N; Suto, H; Toyoda, M | 1 |
| Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB | 1 |
| Chou, TC; Huang, YT; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN | 1 |
| Chockalingam, R; Huen, A; Morse, DC; Pye, A | 1 |
| Ewig, JM; Iyer, P; Mayer, JL | 1 |
| Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H | 1 |
| Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK | 1 |
| Fountas, A; Giotaki, Z; Kalogeropoulos, CD; Tigas, S; Tsatsoulis, A | 1 |
| Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R | 1 |
| Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L | 1 |
| Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS | 1 |
| Fuziwara, CS; Hirokawa, M; Matsuse, M; Mitsutake, N; Miyauchi, A; Nishihara, E; Ogi, T; Saenko, VA; Suzuki, K; Tanimura, S; Yamashita, S | 1 |
| Cohen, MS; Cohen, SM; Mukerji, R; Samadi, AK; Timmermann, BN | 1 |
2 review(s) available for sorafenib and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Topics: Aged; Carcinoma, Hepatocellular; Humans; Iodine Radioisotopes; Kidney Neoplasms; Liquid Biopsy; Liver Neoplasms; Male; Mutation; Proto-Oncogene Proteins B-raf; Quality of Life; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Sorafenib and thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2013 |
1 trial(s) available for sorafenib and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2011 |
19 other study(ies) available for sorafenib and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Middle Aged; Paclitaxel; Phenylurea Compounds; Prognosis; Quinolines; RNA-Seq; Sorafenib; Thyroid Cancer, Papillary; Xenograft Model Antitumor Assays | 2022 |
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
Topics: Antineoplastic Agents; Humans; Neoplasm Recurrence, Local; Paclitaxel; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.
Topics: Glucose; Humans; Immune Checkpoint Inhibitors; Immunity; Paclitaxel; RNA, Messenger; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Microenvironment | 2022 |
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Endoplasmic Reticulum; Humans; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2023 |
Metastatic diffuse follicular variant papillary thyroid cancer without cervical lymph node metastasis presenting with symptoms related to hypopituitarism.
Topics: Aged; Humans; Hypopituitarism; Iodine Radioisotopes; Lymphatic Metastasis; Male; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy | 2023 |
Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Humans; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2023 |
Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Topics: Aged; Antineoplastic Agents; Drug Substitution; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Radiation Tolerance; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sorafenib; Thiophenes; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Hidradenitis suppurativa associated with sorafenib initiation.
Topics: Adult; Antineoplastic Agents; Axilla; Deprescriptions; Hidradenitis Suppurativa; Humans; Male; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2019 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Artery Obstruction; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Choroidal metastasis from papillary thyroid cancer: An unusual feature of a common disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Choroid Neoplasms; Female; Goiter, Nodular; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy | 2017 |
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outcome; Humans; Imatinib Mesylate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiography; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2011 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; COS Cells; DNA, Neoplasm; Humans; Mice; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Withanolides | 2012 |